OBJECTIVES: Inflammatory processes may influence the risk of epithelial ovarian cancer, but available epidemiological evidence is limited and indirect. Circulating C-reactive protein (CRP), a sensitive marker of inflammation, may serve as a direct biological marker of an underlying association. METHODS: The association between ovarian cancer risk and pre-diagnostic circulating CRP was tested in a case-control study nested within three prospective cohorts from Sweden, USA, and Italy. The study included 237 cases and 427 individually matched controls. CRP was measured in stored blood samples by high-sensitivity immunoturbidimetric assay. Odds ratios (OR) and 95% confidence intervals (CI) were calculated by conditional logistic regression. RESULTS: Overall, CRP was not related to risk of ovarian cancer. However, a marked increase in risk was observed for CRP concentrations >10 mg/l: OR (95% CI) 4.4 (1.8-10.9), which remained significant after limiting analyses to cases diagnosed more than two or five years after blood donation (OR 3.0 (1.2-8.0) and 3.6 (1.0-13.2), respectively). Risk of mucinous tumors increased with high CRP, but the number of cases in this analysis was small. CONCLUSION: Study results offer additional support to the concept that chronic inflammation plays a role in epithelial ovarian cancer.
OBJECTIVES: Inflammatory processes may influence the risk of epithelial ovarian cancer, but available epidemiological evidence is limited and indirect. Circulating C-reactive protein (CRP), a sensitive marker of inflammation, may serve as a direct biological marker of an underlying association. METHODS: The association between ovarian cancer risk and pre-diagnostic circulating CRP was tested in a case-control study nested within three prospective cohorts from Sweden, USA, and Italy. The study included 237 cases and 427 individually matched controls. CRP was measured in stored blood samples by high-sensitivity immunoturbidimetric assay. Odds ratios (OR) and 95% confidence intervals (CI) were calculated by conditional logistic regression. RESULTS: Overall, CRP was not related to risk of ovarian cancer. However, a marked increase in risk was observed for CRP concentrations >10 mg/l: OR (95% CI) 4.4 (1.8-10.9), which remained significant after limiting analyses to cases diagnosed more than two or five years after blood donation (OR 3.0 (1.2-8.0) and 3.6 (1.0-13.2), respectively). Risk of mucinous tumors increased with high CRP, but the number of cases in this analysis was small. CONCLUSION: Study results offer additional support to the concept that chronic inflammation plays a role in epithelial ovarian cancer.
Authors: Thomas A Pearson; George A Mensah; R Wayne Alexander; Jeffrey L Anderson; Richard O Cannon; Michael Criqui; Yazid Y Fadl; Stephen P Fortmann; Yuling Hong; Gary L Myers; Nader Rifai; Sidney C Smith; Kathryn Taubert; Russell P Tracy; Frank Vinicor Journal: Circulation Date: 2003-01-28 Impact factor: 29.690
Authors: Alison Talbot-Smith; Lin Fritschi; Mark L Divitini; Dominic F J Mallon; Matthew W Knuiman Journal: Am J Epidemiol Date: 2003-04-01 Impact factor: 4.897
Authors: P Muti; H L Bradlow; A Micheli; V Krogh; J L Freudenheim; H J Schünemann; M Stanulla; J Yang; D W Sepkovic; M Trevisan; F Berrino Journal: Epidemiology Date: 2000-11 Impact factor: 4.822
Authors: L Rosenberg; J R Palmer; R S Rao; P F Coogan; B L Strom; A G Zauber; P D Stolley; S Shapiro Journal: Cancer Epidemiol Biomarkers Prev Date: 2000-09 Impact factor: 4.254
Authors: P Toniolo; P F Bruning; A Akhmedkhanov; J M Bonfrer; K L Koenig; A Lukanova; R E Shore; A Zeleniuch-Jacquotte Journal: Int J Cancer Date: 2000-12-01 Impact factor: 7.396
Authors: Annekatrin Lukanova; Eva Lundin; Arslan Akhmedkhanov; Andrea Micheli; Sabina Rinaldi; Anne Zeleniuch-Jacquotte; Per Lenner; Paola Muti; Carine Biessy; Vittorio Krogh; Franco Berrino; Göran Hallmans; Elio Riboli; Rudolf Kaaks; Paolo Toniolo Journal: Int J Cancer Date: 2003-05-01 Impact factor: 7.396
Authors: Konstantinos K Tsilidis; Casey Branchini; Eliseo Guallar; Kathy J Helzlsouer; Thomas P Erlinger; Elizabeth A Platz Journal: Int J Cancer Date: 2008-09-01 Impact factor: 7.396
Authors: Armin Imhof; Margit Fröhlich; Hannelore Loewel; Nicole Helbecque; Mark Woodward; Phillipe Amouyel; Gordon D O Lowe; Wolfgang Koenig Journal: Clin Chem Date: 2003-04 Impact factor: 8.327
Authors: Britton Trabert; Ligia Pinto; Patricia Hartge; Troy Kemp; Amanda Black; Mark E Sherman; Louise A Brinton; Ruth M Pfeiffer; Meredith S Shiels; Anil K Chaturvedi; Allan Hildesheim; Nicolas Wentzensen Journal: Gynecol Oncol Date: 2014-08-23 Impact factor: 5.482
Authors: Seamus P Whelton; Probal Roy; Brad C Astor; Lin Zhang; Ron C Hoogeveen; Christie M Ballantyne; Josef Coresh Journal: Am J Epidemiol Date: 2013-09-10 Impact factor: 4.897
Authors: Lauren C Peres; Adrianne R Mallen; Mary K Townsend; Elizabeth M Poole; Britton Trabert; Naomi E Allen; Alan A Arslan; Laure Dossus; Renée T Fortner; Inger T Gram; Patricia Hartge; Annika Idahl; Rudolf Kaaks; Marina Kvaskoff; Anthony M Magliocco; Melissa A Merritt; J Ramón Quirós; Anne Tjonneland; Antonia Trichopoulou; Rosario Tumino; Carla H van Gils; Kala Visvanathan; Nicolas Wentzensen; Anne Zeleniuch-Jacquotte; Shelley S Tworoger Journal: Cancer Res Date: 2019-08-28 Impact factor: 12.701
Authors: Danielle M Carrick; Anil K Chaturvedi; Meredith S Shiels; Rao L Divi; Kelly K Filipski; Elizabeth F Hebert; Mukesh Verma; Allan Hildesheim Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-06-24 Impact factor: 4.254
Authors: Bridget Charbonneau; Ellen L Goode; Kimberly R Kalli; Keith L Knutson; Melissa S Derycke Journal: Crit Rev Immunol Date: 2013 Impact factor: 2.214
Authors: Jennifer A Doherty; Allan Jensen; Linda E Kelemen; Celeste L Pearce; Elizabeth Poole; Joellen M Schildkraut; Kathryn L Terry; Shelley S Tworoger; Penelope M Webb; Nicolas Wentzensen Journal: J Natl Cancer Inst Date: 2017-10-01 Impact factor: 13.506
Authors: Elizabeth M Poole; I-Min Lee; Paul M Ridker; Julie E Buring; Susan E Hankinson; Shelley S Tworoger Journal: Am J Epidemiol Date: 2013-08-21 Impact factor: 4.897